Clinical Trial: A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE)

U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07164833) titled 'A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE)' on Aug. 27.

Brief Summary: This is a Randomized, Single-blind, Multi-center, Placebo-controlled, Phase 2a clinical trial of BX-001N to prevent patients from Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and subsequent Major Adverse Kidney Events (MAKE) in approximately 40 participants.

Study Start Date: Aug. 26

Study Type: INTERVENTIONAL

Condition: Ischemia Reperfusion Injury Cardiac Surgery Associated - Acute Kidney Injury

Intervention: DRUG: BX-001N ...